Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION | |||||
|
(502) EVALUATION OF ANTICOAGULATION MANAGEMENT IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA AWAITING DIAGNOSIS CONFIRMATION Alyssa R. George, Katelyn Sylvester, Dareen Kanaan, Delaney Corcoran, Kenneth Lupi, Brian Schuler, Jean M. Connors. Brigham and Women's Hospital, Boston, MA, USA |
||||
|
(503) NATURAL HISTORY OF BLEEDING, TRANSFUSION, AND ANTIBODY PREVALENCE IN A SUBSET OF HERMANSKY-PUDLAK SYNDROME PATIENTS: EFFECTS OF FREEZE-DRIED LYOPHILIZED PLATELET DERIVED HEMOSTAT EX VIVO Keith Moskowitz, Michael Fitzpatrick, Lisa Booth, Maria Abreau-Blanco, Matthew Dickerson, Anna Yu, Anya Derbij, W. Allan Alexander. Cellphire Therapeutics, Inc., Rockville, MD, USA |
||||
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(504) CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT IN VERY HIGH TITER INHIBITOR MURINE MODEL REQUIRES CD19 AND BCMA TARGETING Julia Q. Chau2, Caroline Markmann1, Zheng Zhang1, Michael C. Milone1, Bhavya S. Doshi2,3, Vijay G. Bhoj1, Benjamin J. Samelson-Jones2,3. 1Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 2The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA |
||||
|
(505) NORMALIZATION OF THROMBIN GENERATION RESULTS USING WITHIN-RUN PLASMA NORMALIZATOR SIMULTANEOUSLY. Loic J. Letertre1,2, Pall T. Onundarson1, Jon T. Bergthorsson1,2. 1Landspitali - The National University Hospital, Reykjavik, Iceland 2The University of Iceland, Reykjavik, Iceland |
||||
|
(506) TWO-CENTER EXTERNAL VALIDATION OF A MACHINE LEARNING NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM FOR VENOUS THROMBOEMBOLISM (VTE) ASCERTAINMENT Shengling Ma1, Omid Jafari1, Arash Maghsoudi1, Jennifer La2, 3, Emily Zhou4, Iuliia Kovalenko5, Steven Horng3, 6, Nathanael Fillmore2, 3, Ang Li1, Barbara Lam6. 1Baylor College of Medicine, Houston, TX, USA 2VA Boston Healthcare System, Boston, MA, USA 3Harvard Medical School, Boston, MA, USA 4University of Texas Health Science Center at Houston, Houston, TX, USA 5UPMC Harrisburg, Harrisburg, PA, USA 6Beth Israel Deaconess Medical Center, Boston, MA, USA |
||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(507) CHILD HEMO-TEM OBSERVER-REPORTED OUTCOME MEASURE: UNDERSTANDING AND ASSESSING TREATMENT BURDEN IN CHILDREN WITH HEMOPHILIA Meryl Brod1, Donald M. Bushnell2, Jesper Skov Neergaard3, Anne Kirstine Busk3, Vlady Ostrow4. 1The Brod Group, Mill Valley, CA, USA 2Evidera|PPD, Bethesda, MD, USA 3Novo Nordisk A/S, Søborg, Denmark 4Novo Nordisk Inc., Plainsboro, NJ, USA |
||||
|
(508) LONG-TERM EVALUATION OF LIVER HEALTH IN PARTICIPANTS WHO RECEIVED FIDANACOGENE ELAPARVOVEC: DATA FROM A PHASE 1/2A STUDY WITH UP TO 6 YEARS OF FOLLOW UP Jonathan Ducore1, Lindsey A George2, Ben J Samelson-Jones2, John Rasko3, Catherine McGuinn4, Adam Giermasz1, Jerome Teitel5, Katherine High6, Jeremy Rupon7, Annie Fang7, Lynne Smith7, Priya Patel7, Amit Chhabra7, Frank Plonski7, Matko Kalac7. 1UC David Comprehensive Cancer Center, Sacramento, CA, USA 2Children’s Hospital of Philadelphia, Philadelphia, PA, USA 3Centenary Institute, Sydney, Australia 4Weill Cornell Medical Center, New York, NY, USA 5University of Toronto, Toronto, ON, Canada 6University of Pennsylvania, Philadelphia, PA, USA 7Pfizer Inc, New York, NY, USA |
||||
|
(509) EMICIZUMAB FOR SEVERE VON WILLEBRAND DISEASE (VWD) AND VWD/HEMOPHILIA A: THE EMIVWD STUDY Jonathan Roberts1,2, MIchael Tarantino1,2. 1Bleeding & Clotting Disorders Institute, Peoria, IL, USA 2Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA |
||||
|
(510) DESIGN OF A PROSPECTIVE, OBSERVATIONAL, MULTICENTER STUDY OF THE EFFECTIVENESS OF EFANESOCTOCOG ALFA ON LONG-TERM JOINT HEALTH IN PATIENTS WITH HEMOPHILIA A IN THE UNITED STATES AND JAPAN Jonathan C. Roberts1, Spencer Sullivan2, Eric F. Grabowski3, Doris Quon4, Jennifer Dumont5, Annemieke Willemze6, Nicole Tsao5. 1Bleeding & Clotting Disorders Institute, Peoria, IL, USA 2Mississippi Center for Advanced Medicine, Madison, MS, USA 3Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 4Orthopedic Hemophilia Treatment Center, Los Angeles, CA, USA 5Sanofi, Cambridge, MA, USA 6Sanofi, Amsterdam, Netherlands |
||||
|
(511) SEROPREVALENCE AND SEROCONVERSION AMONG PEOPLE WITH HEMOPHILIA A IN THE UNITED STATES: OBSERVATIONS FROM THE SAAVY (SEROPREVALENCE OF AAV ANTIBODY) STUDY Amy Shapiro1, Leonard A. Valentino2,3, David Hinds4, Manil Vaghela5, Erin Goodman4, Karim Iskander4, George Dela Cerda 4, Kim Schafer6, Steven Pipe7. 1Indiana Hemophilia Thrombosis Center, Indianapolis, IN, USA 2National Bleeding Disorders Foundation, New York, NY, USA 3Rush University, Chicago, IL, USA 4BioMarin Pharmaceutical, Novato, CA, USA 5BioMarin Pharmaceutical, London, United Kingdom 6Hemostasis and Thrombosis Center, UC Davis Health, Sacramento, CA, USA 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA |
||||
|
(512) REAL-WORLD DATA ON EMICIZUMAB PROPHYLAXIS IN OLDER PERSONS WITH HEMOPHILIA A: A RETROSPECTIVE SINGLE CENTER COHORT STUDY Shalini Vemuru1, Stacey Fedewa2,3, Christine Kempton2,3 . 1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA 2Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA 3Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA |
||||
|
(513) CLINICAL UTILITY AND PERFORMANCE OF VON WILLEBRAND FACTOR ACTIVITY ASSAYS IN A NATIONAL REFERENCE LABORATORY: THE VITALANT COAGULATION LABORATORY'S EXPERIENCE WITH THE RISTOCETIN COFACTOR AND VWF:GP1BM ASSAYS Angela Verdoni1, Mason Marshall2, Irina Chibisov1. 1Vitalant Coagulation Laboratory, Pittsburgh, PA, USA 2Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA |
||||
|
(514) BRAIN VOLUMES AND NEUROCOGNITIVE OUTCOMES IN CHILDREN WITH HEMOPHILIA A Silvia Verhofste1, Ahmad Al-Huniti1, 2, Marci Novak1, Amy L. Conrad1, 5, 6, Ellen van der Plas3, 4, Lyndsay Harshman1, 5, 6, Janice M. Staber1, 5, 6. 1Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, USA 2*Current Location - Mayo Clinic, Rochester, MN, USA 3Department of Psychiatry, University of Iowa, Iowa City, IA, USA 4*Current Location -University of Arkansas for Medical Sciences, Pediatrics Arkansas Children's Hospital, Hematology/Oncology, Little Rock, AR, USA 5The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, IA, USA 6Iowa Neuroscience Institute, Iowa City, IA, USA |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(515) SINGLE CENTER RETROSPECTIVE COMPARISON OF BIVALIRUDIN AND HEPARIN FOR THERAPEUTIC ANTICOAGULATION IN PEDIATRIC PATIENTS Clayton Habiger, Shannon Carpenter. Children's Mercy Hospital, Kansas City, MO, USA |
||||
|
(516) TRANSITIONING FROM ORAL FACTOR XA INHIBITOR TO UNFRACTIONATED HEPARIN USING HEPARIN-CALIBRATED ANTI-XA LEVELS Mahnoor M Khan1, Magdalena E Jasinska2, Jeremy P Kosacz3, Erin N Robinson1, Lisa M Thompson3, Brandon Pierce3, Anne E Rose1. 1UW Health - Madison, Madison, WI, USA 2University of Wisconsin School of Pharmacy, Madison, WI, USA 3UW Health - Northern Illinois, Rockford, IL, USA |
||||
|
(517) COVID-19 VENOUS THROMBOEMBOLISM PROPHYLAXIS GUIDELINES Sara McElroy1,2, Emily Cramer1,2, Lauren Amos1,2. 1Children's Mercy Kansas City, Kansas City, MO, USA 2University of Missouri-Kansas City, Kansas City, MO, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(518) BENEFIT OF ALBUMIN INFUSION IN AN ELDERLY CIRRHOTIC PATIENT ON DOAC: ABOUT A CASE . LAMIA AIT OUALI1, FARID SLIMANI2, SAMIA OULARBI1, SAMIR TINE1,3. 1APHP René Muret, Sevran, France 2APHP Jean Verdier, Bondy, France 3APHP Avicenne, Bobigny, France |
||||
|
(519) THE SEVERE VON WILLEBRAND DISEASE PATIENT REGISTRY: A LONGITUDINAL NATURAL HISTORY AND PATIENT OUTCOMES STUDY Johnna Cesta1, Mrinal Gounder1, Christopher Walsh 2, Alice Araphsian1, Jeanette Cesta1, Christina Morgenthaler1. 1VWD Connect Foundation, Wellington, FL, USA 2Icahn School of Medicine Mount Sinai Hospital, New York, NY, USA |
||||
|
(520) EFFECT OF DOAC STOP ON COAGULATION FACTOR ACTIVITY LEVELS Dan A Stephens1, Ronda A Crist1, Karen A Moser1, Allison Carey1,2, Abdulrahman Saadalla1,2, Kristi J Smock1,2. 1ARUP Laboratories Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA 2University of Utah Department of Pathology, Salt Lake City, UT |
||||